View in a different locale / language
United States
A supplement manufacturer added methylcobalamin (Vitamin B12) to a product, expecting to meet label claims. However, testing revealed only ~50% of the claimed amount, triggering an out-of-spec (OOS) result. The client consulted with their contract manufacturer, who confirmed the correct dosage—including overages—had been added during production.
Eurofins Supplement Testing conducted a detailed review of the chromatographic data and discovered that the methylcobalamin had degraded into hydroxycobalamin, a different form of B12. This degradation explained the discrepancy between the expected and measured values.
To address this, the team of experts at Eurofins Supplement Testing recommended switching to a total B12 method that accounts for all active forms. Using this approach, the product tested within specification, confirming the presence of B12 despite the degradation.
With the new method in place, the client understood that:
This case highlights the importance of method selection, material stability, and collaborative investigation when facing unexpected test results. By partnering with Eurofins Supplement Testing, the client not only resolved an out-of-spec issue but gained deeper insight into the behavior of methylcobalamin and how it impacts product performance and labeling.
Advanced analytical tools like ICP-MS and form-specific testing methods empower manufacturers to make informed decisions about raw materials, packaging, and formulation strategies—ensuring regulatory compliance, consumer safety, and brand integrity. As the industry evolves, so must the testing strategies that support it.
Experiencing a challenge and need support? We can help.